SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934
DATE OF REPORT - December 26, 2006
(Date of Earliest Event Reported)
COLUMBIA LABORATORIES, INC.
(Exact name of registrant as specified in its charter)
Commission File No. 1-10352
| Delaware | | 59-2758596 |
| (State of Incorporation) | | (I.R.S. Employer Identification No.) |
| | | |
354 Eisenhower Parkway Livingston, New Jersey | | 07039 |
(Address of principal executive offices) | | Zip Code |
Registrant’s telephone number, including area code: (973) 994-3999
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| o | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| o | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| o | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| o | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
On December 26, 2006, Columbia Laboratories, Inc. (the “Company”), issued a press release entitled, “Columbia Laboratories Closes $40 Million Private Placement of Convertible Subordinated Notes and Completes Acquisition of U.S. Marketing Rights to CRINONE® Progesterone Gel.” A copy of the press release issued by the Company is filed herewith as Exhibit 99.1.
Item 9.01 Financial Statements and Exhibits
(c) Exhibits.
| | 99.1 | Press Release dated December 26, 2006, entitled “Columbia Laboratories Closes $40 Million Private Placement of Convertible Subordinated Notes and Completes Acquisition of U.S. Marketing Rights to CRINONE® Progesterone Gel.” |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: December 26, 2006
| | | |
| | COLUMBIA LABORATORIES, INC. |
|
|
|
| | By: | /s/ James Meer |
| |
James Meer |
| | Senior Vice President, Chief Financial Officer and Treasurer |
Exhibit Index
Exhibit No. | Description |
| | |
| 99.1 | Press Release dated December 26, 2006, entitled “Columbia Laboratories Closes $40 Million Private Placement of Convertible Subordinated Notes and Completes Acquisition of U.S. Marketing Rights to CRINONE® Progesterone Gel.” |
